Venetoclax Plus Hypomethylating Agents Leads to High Response Rates in Older Patients with AML

Daniel Pollyea, MD, shares results from an early, phase Ib study of venetoclax plus decitabine or azacitidine in older patients with treatment-naïve acute myeloid leukemia.

SHARE